ReviewClinical medicine insights. Arthritis and musculoskeletal disorders2020
COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?
Review in Clinical medicine insights. Arthritis and musculoskeletal disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Analysis of the predictive value of microRNA-199b-5p combined with nitric oxide for venous thrombosis in patients undergoing total knee arthroplasty.Journal of orthopaedic surgery and research · 2024Article
- Positive antiphospholipid antibodies: observation or treatment?Journal of thrombosis and thrombolysis · 2023Review
- Cardiac arrest in the setting of probable catastrophic antiphospholipid syndrome in young patient with a history of COVID infection and polyglandular disorder-Case report.SAGE open medical case reports · 2023Article
- Co-infection associated with SARS-CoV-2 and their management.Future science OA · 2022Review
- COVID-19 disease and autoimmune disorders: A mutual pathway.World journal of methodology · 2022Review
- Article
- The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19.Cell reports. Medicine · 2022Article
- Resolution of acute pulmonary embolism using anticoagulation therapy alone in coronavirus disease 2019.Journal of vascular surgery. Venous and lymphatic disorders · 2022Article
- Unusual Presentation of Multisystemic Inflammatory Syndrome.Case reports in medicine · 2022Article
- Application Value of Combined Detection of Anti-Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19.iScience · 2021Article
- Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19.Metabolism: clinical and experimental · 2021Article
- Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients.Annals of the rheumatic diseases · 2021Article
- Colchicine-Resistant Familial Mediterranean Fever With Depressive State Successfully Treated With Escitalopram.Cureus · 2021Article
- Article
- A Case Report of COVID-Associated Catastrophic Antiphospholipid Syndrome Successfully Treated with Eculizumab.Journal of blood medicine · 2021Article
- Oligosymptomatic infection by SARS-Cov-2 in catastrophic antiphospholipid syndrome, a singular coincidence: a case report in an Ecuadorian hospital.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the 2019 novel coronavirus (COVID-19) was first detected in December 2019, research on the complications and fatality of this virus has hastened. Initially, case reports drew an association between COVID-19 and abnormal coagulation parameters. Subsequently, cross-sectional studies found a high prevalence of thrombosis among ICU and non-ICU COVID-19 patients. For that reason, certain studies tried to explain the pathogenic mechanisms of thrombosis, one of which was the emergence of anti-phospholipid antibodies (aPL). Although aPL have been found positive in very few patients, their association with thrombotic events stays debatable. Given the thrombotic manifestations of COVID-19 and the potential role of aPL, the catastrophic form of APS (CAPS) might be a major fatal phenomenon. However, to date, there has been no clear association of CAPS to COVID-19. Moreover, since infections, including viral respiratory similar to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are considered main etiologies for CAPS, it could be possible that SARS-CoV-2 can induce CAPS although no evidence is currently found. High quality studies are needed to develop a clear idea on the pathogenic role of aPL in the progression of thrombosis in COVID-19 patients, and how such patients could be fit into a thromboprophylaxis plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.